MDxHealth SA (MDXH) - Product Pipeline Analysis, 2019 Update

Summary

MDxHealth SA (MDxHealth) develops and commercializes advanced epigenetic and other molecular tests for cancer assessment and the personalized treatment of patients. The companys products portfolio includes ConfirmMDx, which detects absence or presence of prostate cancer; SelectMDx for prostate cancer; and AssureMDx for bladder cancer. Its pipeline products include InformMDx, and MonitorMDx which is being developed for Prostate Cancer Test. MdxHealth tests are based on MSP (Methylation-Specific polymerase chain reaction) technology, a proprietary DNA-based platform. It also offers biomarker development services to many pharmaceutical companies. MDxHealth markets its products through sales forces, partnerships and distributors. The company has operations in, the Netherlands, Belgium and the US. MDxHealth is headquartered in Herstal, Liege, Belgium.

This report is a source for data, analysis, and actionable intelligence on the companys portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company MDxHealth SA
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company


List of Tables
List of Figures
MDxHealth SA Company Overview
MDxHealth SA Company Snapshot
MDxHealth SA Pipeline Products and Ongoing Clinical Trials Overview
MDxHealth SA Pipeline Analysis Overview
Business Description
MDxHealth SA - Key Facts
MDxHealth SA - Major Products and Services
MDxHealth SA Pipeline Products by Development Stage
MDxHealth SA Ongoing Clinical Trials by Trial Status
MDxHealth SA Pipeline Products Overview
(Epi)genetic Diagnostic Assay - Kidney Cancer
(Epi)genetic Diagnostic Assay - Kidney Cancer Product Overview
AssureMDx - Bladder Cancer
AssureMDx - Bladder Cancer Product Overview
Bladder ConfirmMDx
Bladder ConfirmMDx Product Overview
Bladder RecurMdx
Bladder RecurMdx Product Overview
ClinicalMDx - Cervical Cancer
ClinicalMDx - Cervical Cancer Product Overview
ConfirmMDx - Prostate Cancer
ConfirmMDx - Prostate Cancer Product Overview
ConfirmMDx - Prostate Cancer Clinical Trial
ConfirmMDx Lung Cancer Test
ConfirmMDx Lung Cancer Test Product Overview
Diagnostic Test - Urologic Cancer
Diagnostic Test - Urologic Cancer Product Overview
Epigenetic Biomarker Test - Prostate Cancer
Epigenetic Biomarker Test - Prostate Cancer Product Overview
InformMDx - Colon Cancer
InformMDx - Colon Cancer Product Overview
InformMDx - Prostate Cancer CLIA Test
InformMDx - Prostate Cancer CLIA Test Product Overview
InformMDx Prognostic Test - Prostate Cancer
InformMDx Prognostic Test - Prostate Cancer Product Overview
Liquid Biopsy Epigenetic Assay - Oral Cancer
Liquid Biopsy Epigenetic Assay - Oral Cancer Product Overview
Molecular Diagnostic Test - Bladder Cancer
Molecular Diagnostic Test - Bladder Cancer Product Overview
MonitorMDx - Prostate Cancer
MonitorMDx - Prostate Cancer Product Overview
PharmacoDx - Breast Cancer
PharmacoDx - Breast Cancer Product Overview
PharmacoDx - Lung Cancer
PharmacoDx - Lung Cancer Product Overview
PredictMDx - Colon Cancer
PredictMDx - Colon Cancer Product Overview
RecurMDx - Prostate Cancer
RecurMDx - Prostate Cancer Product Overview
MDxHealth SA - Key Competitors
MDxHealth SA - Key Employees
MDxHealth SA - Key Employee Biographies
MDxHealth SA - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
MDxHealth SA, Recent Developments
Aug 29, 2019: MDxHealth reports half year 2019 financial results and strategic update
Aug 26, 2019: MDxHealth announces favorable draft medicare coverage for the SelectMDx test
Jun 10, 2019: MDxHealth: Multi-center study validates SelectMDxs high negative predictive value and sensitivity
May 03, 2019: MDxHealth: Presentation of new data for MDxHealths prostate cancer diagnostic tests at AUA 2019 Annual Meeting
Apr 24, 2019: MDxHealth provides Q1 2019 business update
Mar 18, 2019: MDxHealth announces positive data from Pan-European clinical validation study of SelectMDx
Mar 05, 2019: MDxHealth : SelectMDx Liquid Biopsy Test for Prostate Cancer Included in the 2019 Italian Society of Urology Guidelines
Feb 28, 2019: MDxHealth reports financial year 2018 results and provides outlook for 2019
Feb 19, 2019: MDxHealth names Michael K. McGarrity as CEO
Feb 15, 2019: MDxHealth Announces Presentation of Positive Data for SelectMDx and ConfirmMDx in Prostate Cancer Diagnosis
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

List Of Tables

List of Tables
MDxHealth SA Pipeline Products and Ongoing Clinical Trials Overview
MDxHealth SA Pipeline Products by Equipment Type
MDxHealth SA Pipeline Products by Indication
MDxHealth SA Ongoing Clinical Trials by Trial Status
MDxHealth SA, Key Facts
MDxHealth SA, Major Products and Services
MDxHealth SA Number of Pipeline Products by Development Stage
MDxHealth SA Pipeline Products Summary by Development Stage
MDxHealth SA Ongoing Clinical Trials by Trial Status
MDxHealth SA Ongoing Clinical Trials Summary
(Epi)genetic Diagnostic Assay - Kidney Cancer - Product Status
(Epi)genetic Diagnostic Assay - Kidney Cancer - Product Description
AssureMDx - Bladder Cancer - Product Status
AssureMDx - Bladder Cancer - Product Description
Bladder ConfirmMDx - Product Status
Bladder ConfirmMDx - Product Description
Bladder RecurMdx - Product Status
Bladder RecurMdx - Product Description
ClinicalMDx - Cervical Cancer - Product Status
ClinicalMDx - Cervical Cancer - Product Description
ConfirmMDx - Prostate Cancer - Product Status
ConfirmMDx - Prostate Cancer - Product Description
ConfirmMDx - Prostate Cancer - Prospective Validation of Prostate Biomarkers for Repeat Biopsy: The PRIORITY Study
ConfirmMDx Lung Cancer Test - Product Status
ConfirmMDx Lung Cancer Test - Product Description
Diagnostic Test - Urologic Cancer - Product Status
Diagnostic Test - Urologic Cancer - Product Description
Epigenetic Biomarker Test - Prostate Cancer - Product Status
Epigenetic Biomarker Test - Prostate Cancer - Product Description
InformMDx - Colon Cancer - Product Status
InformMDx - Colon Cancer - Product Description
InformMDx - Prostate Cancer CLIA Test - Product Status
InformMDx - Prostate Cancer CLIA Test - Product Description
InformMDx Prognostic Test - Prostate Cancer - Product Status
InformMDx Prognostic Test - Prostate Cancer - Product Description
Liquid Biopsy Epigenetic Assay - Oral Cancer - Product Status
Liquid Biopsy Epigenetic Assay - Oral Cancer - Product Description
Molecular Diagnostic Test - Bladder Cancer - Product Status
Molecular Diagnostic Test - Bladder Cancer - Product Description
MonitorMDx - Prostate Cancer - Product Status
MonitorMDx - Prostate Cancer - Product Description
PharmacoDx - Breast Cancer - Product Status
PharmacoDx - Breast Cancer - Product Description
PharmacoDx - Lung Cancer - Product Status
PharmacoDx - Lung Cancer - Product Description
PredictMDx - Colon Cancer - Product Status
PredictMDx - Colon Cancer - Product Description
RecurMDx - Prostate Cancer - Product Status
RecurMDx - Prostate Cancer - Product Description
MDxHealth SA, Key Employees
MDxHealth SA, Key Employee Biographies
MDxHealth SA, Subsidiaries
Glossary

List Of Figures

List of Figures
MDxHealth SA Pipeline Products by Equipment Type
MDxHealth SA Pipeline Products by Development Stage
MDxHealth SA Ongoing Clinical Trials by Trial Status

MDxHealth SA (MDXH) - Product Pipeline Analysis, 2019 Update

MDxHealth SA (MDxHealth) develops and commercializes advanced epigenetic and other molecular tests for cancer assessment and the personalized treatment of patients. The companys products portfolio includes ConfirmMDx, which detects absence

USD 750 View Report

MDxHealth SA (MDXH) - Product Pipeline Analysis, 2018 Update

MDxHealth SA (MDxHealth) develops and commercializes advanced epigenetic and other molecular tests for cancer assessment and the personalized treatment of patients. The companys products portfolio includes ConfirmMDx, which detects absence

USD 750 View Report

MDxHealth SA (MDXH) - Product Pipeline Analysis, 2018 Update

MDxHealth SA (MDxHealth) develops and commercializes advanced epigenetic and other molecular tests for cancer assessment and the personalized treatment of patients. The companys products portfolio includes ConfirmMDx, which detects absence

USD 750 View Report

MDxHealth SA (MDXH) - Financial and Strategic SWOT Analysis Review

MDxHealth SA (MDXH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled to bring

USD 125 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available